Clinical Progression of Patients with COVID-19 in Shanghai, China
Overview
Authors
Affiliations
Background: Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19.
Methods: In this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020.
Results: Of the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2-7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12-20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8-11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10-12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR] = 1.06) and CD4 T cell count (OR = 0.55 per 100 cells/ul increase) were independently associated with ICU admission.
Conclusions: The majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19.
Interaction between coronaviruses and the autophagic response.
Yu J, Ge S, Li J, Zhang Y, Xu J, Wang Y Front Cell Infect Microbiol. 2024; 14:1457617.
PMID: 39650836 PMC: 11621220. DOI: 10.3389/fcimb.2024.1457617.
Dynamics of cytokine and antibody responses in community versus hospital SARS-CoV-2 infections.
Singh T, Macintyre A, Burke T, Anderson J, Petzold E, Stover E Front Immunol. 2024; 15:1468871.
PMID: 39650666 PMC: 11621060. DOI: 10.3389/fimmu.2024.1468871.
Andrejkovits A, Hutanu A, Manu D, Dobreanu M, Vasiesiu A Int J Mol Sci. 2024; 25(22).
PMID: 39595989 PMC: 11593669. DOI: 10.3390/ijms252211921.
Alharbi A, Aljerian N, Alghamdi H, Binhotan M, Alsultan A, Arafat M Healthcare (Basel). 2024; 12(19).
PMID: 39408119 PMC: 11476501. DOI: 10.3390/healthcare12191939.
Zaidan M, Puebla Neira D, Polychronopoulou E, Yong-Fang K, Sharma G PLoS One. 2024; 19(6):e0303509.
PMID: 38900737 PMC: 11189225. DOI: 10.1371/journal.pone.0303509.